Patient access to Gilead’s remdesivir curtailed as clinical studies wind down

Organisation: Position: Deadline Date: Location:

Gilead Sciences‘ two clinical studies of its potential coronavirus treatment remdesivir will wind down by the end of May, closing off a path of patient access to the antiviral medication.

Reuters Health reports that this is according to US researchers involved in the studies. The drug was given emergency use authorisation by the US Food and Drug Administration on 1 May, but hospitals are concerned about access. “We would like to see equitable and transparent distribution of this very precious resource,” Dr Helen Boucher, chief of infectious diseases at Tufts Medical Centre in Boston, said.

The report says Gilead’s studies – one in patients with severe COVID-19 and the other in moderate disease – have enrolled around 8,000 subjects. The trials are “open label” meaning they do not compare the treatment to a placebo and participants know they are getting the drug.

Interest in Gilead’s drug has been high given some promising early data and the lack of approved treatments or preventive vaccines for COVID-19, the report says. Preliminary results from a trial conducted by the US National Institutes of Health showed that remdesivir cut hospital stays by 31% compared to a placebo.

The NIH is now studying remdesivir alone compared to remdesivir in combination with Olumiant, an anti-inflammatory drug approved for rheumatoid arthritis and sold by Eli Lilly and Co.

The report says remdesivir is still available on a compassionate use basis for pregnant women or children under the age of 18, but most COVID-19 patients will soon have access only under the emergency use authorisation. “We participate in the Gilead clinical trials here at Tufts,” Boucher said. “We were notified that they will wind down … no later than the end of May.” Gilead told Tufts it is transitioning to product distribution under the emergency use authorization.

The report says researchers at Boston’s Beth Israel Deaconess Medical Centre have also heard that the two Gilead studies would stop enrolling patients by the end of the month.

Gilead, which has pledged to donate 1.5m vials of remdesivir to fight the global pandemic, did not respond to requests for comment. The drug is administered by infusion in hospital.

The US Department of Health and Human Services said Gilead had commited to supply US hospitals with around 607,000 vials of remdesivir – about 40% of the donation, or enough to treat at least 78,000 patients. After doctors had questioned the transparency of the allocation process, the federal agency said state health departments would distribute the drug.

Gilead has said early results from its first study showed that the drug improved outcomes for patients with severe COVID-19, and it plans to announce findings from its second study in moderate patients later this month.

Full Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.